Biblio Discovery — Demo Discovery Service

3 hasil untuk "Stephan Stenglein"

Menampilkan 1–3 · 1,10 detik · RSS

  1. Artikel Jurnal

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of zapnometinib: results from a phase I clinical study

    Stephan Stenglein; Julian Volk; Yvonne Füll dkk.

    Frontiers in Pharmacology, Vol. 17 · 2026 · Inggris · DOAJ Scopus

    IntroductionZapnometinib (ATR-002) is a selective MEK inhibitor designed to modulate the MAPK/ERK pathway, which plays a key role in viral infections and inflammatory diseases. Clinical characterization of its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) is essential to…

  2. Artikel Jurnal

    Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trialResearch in context

    Gernot Rohde; Stephan Stenglein; Hans Prozesky dkk.

    EClinicalMedicine, Vol. 65 · 2023 · Inggris · DOAJ Scopus

    Summary: Background: Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. We aimed to investigate the safety and efficacy of zapnometinib in patients with COVID-19. Methods: In this randomised, double-blind…

  3. Artikel Jurnal

    Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients

    Yvonne Füll; Lara M. Schüssele; Hazem Hamza dkk.

    Frontiers in Immunology, Vol. 16 · 2025 · Inggris · DOAJ Scopus

    IntroductionIn severe COVID-19, direct-acting antiviral drugs were not effective in hyperinflammatory stages and steroid treatment may weaken host immunity. The MEK inhibitor zapnometinib, as a host-targeting drug, has demonstrated promising efficacy against severe acute viral infections…